Globus Medical (GMED) Stock Price, News & Analysis

Company Overview

Globus Medical, Inc. (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room. The ExcelsiusGPS® robotic guidance system, for example, integrates real-time imaging with robotic arm technology to enable surgeons to perform complex procedures with greater accuracy. The company also offers an array of trauma and orthopaedic solutions, such as bone graft substitutes and joint reconstruction implants, to address a broad spectrum of musculoskeletal conditions.

Globus Medical serves surgeons and patients across North America, Europe, Asia, Latin America and the Middle East through a combination of direct sales and distribution partnerships. Under the leadership of founder and Executive Chairman David C. Paul and President and Chief Executive Officer Glenn J. Shapiro, the company has built a global commercial infrastructure and invested in research and development to drive innovation. Its commitment to surgical education and customer support further reinforces its position in the competitive medical device landscape.

Key Stats

• Today's Range: $88.28 to $91.25
• 50-Day Range: $83.51 to $96.68
• 52-Week Range: $51.79 to $101.40
• Volume: 1.37 million shs
• Average Volume: 976,495 shs
• Market Capitalization: $12.08 billion
• P/E Ratio: 22.67
• Dividend Yield: N/A
• Price Target: $104.36
• Consensus Rating: Moderate Buy

Globus Medical Stock Analysis - MarketRank™

Globus Medical scored higher than 89% of companies evaluated by MarketBeat, and ranked 66th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Globus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 3 strong buy ratings, 8 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Globus Medical has a consensus price target of $104.36, representing about 16.9% upside from its current price of $89.30.

Amount of Analyst Coverage

Globus Medical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.42%

Earnings Growth

Earnings for Globus Medical are expected to grow by 9.42% in the coming year, from $4.46 to $4.88 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Globus Medical is 22.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.23.

Price to Earnings Ratio vs. Sector

The P/E ratio of Globus Medical is 22.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.35.

Price to Earnings Growth Ratio

Globus Medical has a PEG Ratio of 2.10. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Globus Medical has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.01% of the float of Globus Medical has been sold short.

Short Interest Ratio / Days to Cover

Globus Medical has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Globus Medical has recently increased by 17.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Globus Medical does not currently pay a dividend.

Dividend Growth

Globus Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.27

News Sentiment

Globus Medical has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Globus Medical this week, compared to 5 articles on an average week.

Search Interest

Only 6 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.

MarketBeat Follows

7 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,766,700.00 in company stock.

Percentage Held by Insiders

18.38% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GMED Stock Analysis - Frequently Asked Questions

How have GMED shares performed this year?

Globus Medical's stock was trading at $87.39 at the start of the year. Since then, GMED shares have increased by 2.2% and is now trading at $89.3040.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) announced its earnings results on Tuesday, February, 24th. The medical device company reported $1.28 EPS for the quarter, beating analysts' consensus estimates of $1.06 by $0.22. Globus Medical's revenue for the quarter was up 25.7% on a year-over-year basis.
Read the conference call transcript.

Is Globus Medical buying back stock?

Globus Medical's board approved a stock buyback plan on Thursday, May 15th 2025, which allows the company to buy back $500,000,000 in shares, according to EventVestor. This means that the company could buy up to 6.3% of its shares through open market purchases. Shares buyback plans are often an indication that the company's leadership believes its stock is undervalued.

When did Globus Medical IPO?

Globus Medical (GMED) raised $200 million in an IPO on Friday, August 3rd 2012. The company issued 11,764,705 shares at $16.00-$18.00 per share.

Who are Globus Medical's major shareholders?

Top institutional investors of Globus Medical include Boston Trust Walden Corp (0.93%), Bank of New York Mellon Corp (0.55%), Stephens Investment Management Group LLC (0.53%) and Swedbank AB (0.42%). Insiders that own company stock include David D Davidar, Ann D Rhoads, Leslie V Norwalk, Stephen T Zarrilli, Daniel T Scavilla, Dan Lemaitre, Kyle Kline, Kelly Huller and Keith W Pfeil.
View institutional ownership trends.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Globus Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/24/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:GMED
• CIK: 1237831
• Web: www.globusmedical.com
• Phone: (610) 930-1800
• Fax: 610-930-2042
• Employees: 6,000
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Globus Medical: $104.36
• High Price Target: $123.00
• Low Price Target: $64.00
• Potential Upside/Downside: +16.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.94
• Trailing P/E Ratio: 22.67
• Forward P/E Ratio: 20.02
• P/E Growth: 2.1
• Net Income: $537.87 million
• Net Margins: 18.30%
• Pretax Margin: 20.59%
• Return on Equity: 12.57%
• Return on Assets: 10.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.26
• Quick Ratio: 2.74

Sales & Book Value

• Annual Sales: $2.94 billion
• Price / Sales: 4.11
• Cash Flow: $6.23 per share
• Price / Cash Flow: 14.33
• Book Value: $33.86 per share
• Price / Book: 2.64

Miscellaneous

• Outstanding Shares: 135,250,000
• Free Float: 110,393,000
• Market Cap: $12.08 billion
• Optionable: Optionable
• Beta: 1.00